|Related Categories||Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Cancer Research, Cell Biology, Cell Signaling and Neuroscience,|
|solubility||DMSO: ≥20 mg/mL|
|Gene Information||human ... EGFR(1956), ERBB2(2064)|
Potent and selective dual inhibitor of EGFR (IC50 = 0.016 mM) and ErbB-2 receptor tyrosine kinase.
Sold for research purposes under agreement from GlaxoSmithKline
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Rusnack, D. W., et al. CRC Handbook of Microbiology 61, 7196, (2001)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?